FASN and prostate carcinoma: The selective FASN inhibitor IPI‐9119 [24] reduced both cell migration (Figure 5A, left panel, and 5B) and invasion (Figure 5A, right panel, and 5C) in Pten+/− prostate cancer cells, but not their viability (Figure 5D).